MSD chooses partner to develop ‘game-changing’ cancer therapies
January 6, 2016Research and Development CPABs, Cancer, Cell-Penetrating Alphabodies, Complix, MSD, autoimmune diseases
MSD has entered a research collaboration with biopharma company Complix, using the company’s proprietary technology to develop new treatments for …
Sanofi abandons MannKind’s failed inhalable insulin
January 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing Afrezza, Mannkind, Sanofi, insulin
Sanofi is to exit a licensing and co-marketing deal with MannKind for the inhalable insulin Afrezza, after disappointing sales figures …
Gilead success in late-stage hepatitis B trials
January 5, 2016Research and Development, Sales and Marketing Gilead, hepatitis B, phase III
Two Phase III trials evaluating Gilead treatments in chronic hepatitis B virus (HBV) infection have met their primary objectives, showing …
Eli Lilly predicts revenue growth in 2016
January 5, 2016Research and Development, Sales and Marketing Eli Lilly, financial reports, marketing, sales
Eli Lilly has set out its financial guidance for 2016, predicting an increase in sales to between $20.2 and $20.7 …
BioMarin elects former Allergan CEO to board
January 5, 2016Medical Communications, Research and Development, Sales and Marketing
BioMarin Pharmaceutical has announced the election of former Allergan chief executive, David Pyott, to the company’s board of directors. Pyott served …
Actelion’s Uptravi goes on sale
January 5, 2016Manufacturing and Production, Sales and Marketing Actelion, PAH, Uptravi, pulmonary arterial hypertension, pulmonary hypertension, selexipag
Swiss pharma firm Actelion has put its new drug for pulmonary hypertension, Uptravi, up for sale in the US, weeks …
Bayer and Baxalta in separate €1 billion-plus deals
January 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ascensia diabetes care, Baxalta, Bayer, diabetes, panasonic, symphogen
Baxalta has signed a deal with Symphogen potentially worth as much as €1.4 billion, under which the companies will develop …
Pfizer, Merck and Syndax in ovarian cancer trial collaboration
January 5, 2016Manufacturing and Production, Research and Development Merck, Pfizer, Syndax Pharmaceuticals, avelumab, entinostat, ovarian cancer
Pfizer, Merck and Syndax Pharmaceuticals have announced a collaboration to test avelumab, in combination with Syndax’s entinostat, in patients with …
Merck’s Erbitux approved for NHS Wales
January 5, 2016Manufacturing and Production, Sales and Marketing Erbitux, Merck, cetuximab, colorectal cancer, metastatic colorectal cancer
The All Wales Medicines Strategy Group has recommended Merck’s Erbitux in combination with chemotherapy for restricted use in the NHS …
Novartis’ Cosentyx shows benefits in Phase III AS trials
January 4, 2016Research and Development, Sales and Marketing Cosentyx, Novartis, Secukinumab, ankylosing spondylitis
Novartis says results from two Phase III studies for Cosentyx in ankylosing spondylitis (AS) showing significant clinical improvements versus placebo.Results …
Former Merck R&D expert joins RedX Pharma board
January 4, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing RedX Pharma
Dr Bernhard Kirschbaum, 57, has been added as a non-executive director at RedX Pharma with immediate effect. Kirschbaum is a …
Reports: $32bn Shire takeover of Baxalta close to done deal
January 4, 2016Sales and Marketing Baxalta, Shire, acquisition, merger
The deal may have failed to get over the line in 2015, but reports suggest the mega merger is to …
‘Rejuvenated’ pharma manufacturing set for 2016 comeback
January 4, 2016Manufacturing and Production, Sales and Marketing Employment, industry, manufacturing, patent cliff, pharma, production
The pharma industry has been singled out for its strong performance in 2015, in a report which says manufacturing in …
Takeda and Teva set out generics joint venture plan
January 4, 2016Sales and Marketing Takeda, Teva, generics, joint venture
Takeda and Teva have detailed plans for a new joint venture to create a new company to market off-patent generic …
KaloBios files for bankruptcy after Shkreli arrest
January 4, 2016Sales and Marketing KaloBios, Martin Shkreli
KaloBios has filed for bankruptcy in the wake of chief executive Martin Shkreli’s arrest on securities fraud charges last month …
Season’s greetings from Pharmafocus
December 25, 2015Merry Christmas and a happy new year from all at Pharmafocus!We will be back on Monday 4 January with all …
WHO to review MSD’s Ebola vaccine for emergency use
December 24, 2015Manufacturing and Production, Research and Development Ebola vaccine, Ebola virus, MSD, WHO, Zebov
The World Health Organisation (WHO) has accepted MSD’s application for the company’s investigational Ebola vaccine, V920 (Zebov), to be reviewed …
J&J and Purdue settle Kentucky lawsuits for $39.5 million
December 24, 2015Sales and Marketing Johnson and Johnson, Kentucky, OxyContin, Purdue Pharma, Risperdal, lawsuits
Johnson & Johnson and Purdue Pharma have settled separate lawsuits with the US state of Kentucky for a total of …
Boehringer Ingelheim invests in Europe
December 24, 2015Manufacturing and Production, Sales and Marketing Austria, Biberach, Boehringer Ingelheim, Vienna, biologicals, manufacturing, production
Boehringer Ingelheim will kick off its pharma investments in 2016 with a half a billion Euro outlay and plans to …
OTC drugs market boosted by growing patient demand
December 24, 2015Manufacturing and Production, Sales and Marketing GBI Research, OTC, generics, over the counter
Increasing pressures from customers, drug manufacturers and regulators to convert prescription medications to over-the-counter (OTC) non-prescription status is driving growth …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
